BioPharmSignal logoBioPharmSignal

Biotech News

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (ATRA)Atara Biotherapeutics, Inc.Earnings

ATRA (ATRA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is atra.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ATRAAtara Biotherapeutics, Inc.2026-08-12 20:05 EST

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

APGEApogee Therapeutics2026-08-10 11:00 EST

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

View all latest news

Atara Biotherapeutics, Inc.

Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Its platform does not require T-cell-receptor or HLA gene editing. Tabelecleucel Tabelecleucel, also known as tab-cel or EBVALLO, is an allogeneic EBV-specific T-cell...

Recent company news

ATRAAtara Biotherapeutics, Inc.2026-08-12 20:05 EST

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-06-12 20:00 EST

Atara Biotherapeutics Announces Changes to Its Board of Directors

ATRAAtara Biotherapeutics, Inc.2026-05-12 20:05 EST

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

ATRAAtara Biotherapeutics, Inc.2026-05-07 12:05 EST

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

ATRAAtara Biotherapeutics, Inc.2026-03-16 20:05 EST

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Stock data

Close
8.36 USD
Market cap
89.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States